Evidence map›Paper›PMID 37270534›Full record

ArticleNature communications2023

Intrinsic TGF-β signaling attenuates proximal tubule mitochondrial injury and inflammation in chronic kidney disease.

Merve Kayhan, Judith Vouillamoz, Daymé Gonzalez Rodriguez, Milica Bugarski, Yasutaka Mitamura, Julia Gschwend, Christoph Schneider, Andrew Hall, David Legouis, Cezmi A Akdis and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Lactate-Mediated Lysine Lactylation in Renal Fibrosis: Current Progress and Challenges.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Merve KayhanInstitute of Physiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-6089-5086
Judith VouillamozInstitute of Physiology, University of Zurich, Zurich, Switzerland.ORCID 0009-0004-3798-061X
Daymé Gonzalez RodriguezFunctional Genomics Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
Milica BugarskiInstitute of Anatomy, University of Zurich, Zurich, Switzerland.
Yasutaka MitamuraSwiss Institute of Allergy and Asthma Research, University of Zurich, Zurich, Switzerland.
Julia GschwendInstitute of Physiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7212-4393
Christoph SchneiderInstitute of Physiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0452-2960
Andrew HallInstitute of Anatomy, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-6328-7892
David LegouisLaboratory of Nephrology, Department of Medicine and Cell Physiology, Hospital and University of Geneva, Geneva, Switzerland.ORCID 0000-0002-2924-9737
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research, University of Zurich, Zurich, Switzerland.
Leary PeterFunctional Genomics Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID 0000-0003-1430-6185
Hubert RehrauerFunctional Genomics Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-7612-9394
Leslie GewinDepartment of Internal Medicine, Division of Nephrology, Washington University, St. Louis, USA.ORCID 0000-0002-6146-1092
Roland H WengerInstitute of Physiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7592-4839
Stellor Nlandu KhodoInstitute of Physiology, University of Zurich, Zurich, Switzerland. stellor.nlandukhodo@uzh.ch.ORCID 0000-0001-6676-6648
University of Zurich · CHUniversity of Geneva · CHWashington University in St. Louis · US

Funding

TGF-beta Pathways that Protect Epithelia in Chronic Renal InjuryR01DK108968 · NIDDK · WASHINGTON UNIVERSITY · PI GEWIN, LESLIE S · 2016 to 2025
$3.7M
The Role of Fatty Acid Oxidation in Injured Kidney TubulesI01BX003425 · VA · VETERANS HEALTH ADMINISTRATION · PI Leslie S Gewin · 2018 to 2026
–
BLRD VA I01 BX003425NIDDK NIH HHS R01 DK108968
6 · The paper itself

Abstract

Excessive TGF-β signaling and mitochondrial dysfunction fuel chronic kidney disease (CKD) progression. However, inhibiting TGF-β failed to impede CKD in humans. The proximal tubule (PT), the most vulnerable renal segment, is packed with giant mitochondria and injured PT is pivotal in CKD progression. How TGF-β signaling affects PT mitochondria in CKD remained unknown. Here, we combine spatial transcriptomics and bulk RNAseq with biochemical analyses to depict the role of TGF-β signaling on PT mitochondrial homeostasis and tubulo-interstitial interactions in CKD. Male mice carrying specific deletion of Tgfbr2 in the PT have increased mitochondrial injury and exacerbated Th1 immune response in the aristolochic acid model of CKD, partly, through impaired complex I expression and mitochondrial quality control associated with a metabolic rewiring toward aerobic glycolysis in the PT cells. Injured S3T2 PT cells are identified as the main mediators of the maladaptive macrophage/dendritic cell activation in the absence of Tgfbr2. snRNAseq database analyses confirm decreased TGF-β receptors and a metabolic deregulation in the PT of CKD patients. This study describes the role of TGF-β signaling in PT mitochondrial homeostasis and inflammation in CKD, suggesting potential therapeutic targets that might be used to mitigate CKD progression.

Indexed as

Renal Insufficiency, ChronicSignal TransductionAnimalsFibrosisHumansInflammationKidneyMaleMiceMitochondriaReceptor, Transforming Growth Factor-beta Type IITransforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITransforming Growth Factor beta

Identifiers

PMID37270534
PMCPMC10239443
OpenAlexW4379260351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.